This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
Stifel Nicolaus 2012 Healthcare Conference10:55 am ET on September 5, 2012 in Boston, MAPresenter: Gregory Perry, Executive Vice President and CFO
Morgan Stanley Global Healthcare Conference8:00 am ET on September 12, 2012 in New York, NYPresenter: Daniel Junius, President and CEO
UBS Global Life Sciences Conference3:00 pm ET on September 20, 2012 in New York, NYPresenter: Daniel Junius, President and CEO
A webcast of each presentation can be accessed live through the “Investor Information” section of the Company’s website,
www.immunogen.com; a replay of each presentation will be available at the same location for one week.
The Company is also participating in the Credit Suisse 3
rd Annual Small & Mid Cap Conference on September 21, 2012 in New York, NY.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-killing agents specifically to tumor cells. There are now ten TAP compounds in clinical development, of which three are wholly owned by the Company. ImmunoGen’s collaborative partners include Amgen, Bayer HealthCare, Biotest, Lilly, Novartis, Roche, and Sanofi. A marketing application for trastuzumab emtansine (T-DM1), the most advanced compound using ImmunoGen’s TAP technology, has been submitted in the US. Roche is developing this compound under an agreement between ImmunoGen and Genentech, a member of the Roche Group. More information about ImmunoGen can be found at